Drug Trial Radar · NCT03372200
Febuxostat-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout
Last checked: Nov 19, 2026Latest source record: Sep 24, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
203
Actual
Start
Jan 9, 2018
Primary completion
Jun 4, 2018
Study completion Jul 5, 2018
Sponsor
- Lead sponsor
- Mochida Pharmaceutical Company, Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Fuji Yakuhin Co., Ltd.
- First posted
- Dec 13, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
FYU-981 or Febuxostat are administrated to hyperuricemia patients (underexcretion and mixed types) with or without gout for 14 weeks to compare the efficacy and safety of these drugs by the method of multicenter, randomized, double-blind, ascending dose regimen.
Conditions
- Hyperuricemia With or Without Gout
Interventions
FYU-981Drug
Oral daily dosing for 14 weeks
FebuxostatDrug
Oral daily dosing for 14 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent reduction from baseline in serum urate level at the final visitTime frame: 14 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mochida Investigational sites
Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.